Maiwald blog articles
EPO: New referral to the Enlarged Board of Appeal – post-filed experimental evidence and plausibility; G 2/21
At last: the long-awaited referral to the Enlarged Board of Appeal with respect to one of the most controversially discussed issues in EP patent matters in recent times, i.e. ...
Continue reading
Review of the Vertragshandbuch Pharma and Life Sciences
The updated handbook provides a comprehensive collection of annotated sample contracts for all common regulatory areas related to a product's life cycle, from development to c...
Continue reading
The Closed Season Is Over – Vertical Antitrust Violations Are Not Trivial Offences
It is a widespread misconception that only horizontal antitrustviolations (such as in truck, beer or sausage cartels), i.e. practices between competitors that violate antitrus...
Continue reading
What Are the Possibilities to Terminate a Contract and Recover Losses From a Contractual Partner either Guilty or Suspected of Corruption?
The need for more stringent anti-corruption and compliance measures to prevent active and passive corruption, contractual obligations to compel businesses to introduce complia...
Continue reading
Mandatory Information in the Advertising of Medicinal Products
In addition to the prohibition of advertising gifts according to Section 7 of the Law on Advertising in the Health Care System (HWG) (see the blog post of
Continue reading
